Evidence map›Paper›PMID 34829842›Full record

ReviewBiomedicines2021

An Epigenetic Insight into NLRP3 Inflammasome Activation in Inflammation-Related Processes.

Aroa Baragaño Raneros, Cristian Ruiz Bernet, Aida Bernardo Flórez, Beatriz Suarez-Alvarez

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. New Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2024
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Aroa Baragaño RanerosTranslational Immunology Laboratory, Instituto de Investigación Biosanitaria del Principado de Asturias (ISPA), Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain.
Cristian Ruiz BernetTranslational Immunology Laboratory, Instituto de Investigación Biosanitaria del Principado de Asturias (ISPA), Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain.ORCID 0000-0003-2546-0591
Aida Bernardo FlórezTranslational Immunology Laboratory, Instituto de Investigación Biosanitaria del Principado de Asturias (ISPA), Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain.
Beatriz Suarez-AlvarezTranslational Immunology Laboratory, Instituto de Investigación Biosanitaria del Principado de Asturias (ISPA), Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain.
Instituto de Investigación Biosanitaria de Granada · ES

Funding

Spanish Institute of Health Carlos III PI17/01244, PI20/00639 and PI19/00184
6 · The paper itself

Abstract

Aberrant NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome activation in innate immune cells, triggered by diverse cellular danger signals, leads to the production of inflammatory cytokines (IL-1β and IL-18) and cell death by pyroptosis. These processes are involved in the pathogenesis of a wide range of diseases such as autoimmune, neurodegenerative, renal, metabolic, vascular diseases and cancer, and during physiological processes such as aging. Epigenetic dynamics mediated by changes in DNA methylation patterns, chromatin assembly and non-coding RNA expression are key regulators of the expression of inflammasome components and its further activation. Here, we review the role of the epigenome in the expression, assembly, and activation of the NLRP3 inflammasome, providing a critical overview of its involvement in the disease and discussing how targeting these mechanisms by epigenetic treatments could be a useful strategy for controlling NLRP3-related inflammatory diseases.

Indexed as

acetylationDNA methylationepigeneticsIL-1βinflammasomeNLRP3pyroptosis

Identifiers

PMID34829842
PMCPMC8615487
OpenAlexW3209310529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.